SEC Form 4 · accession 0001567619-18-001566
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Aaron Schuchart
Officer — Chief Business Officer
Period of report
Aug 17, 2018
Accepted (ET)
Aug 21, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2018 | M | 8,500 | $3.50 | A | 8,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.50 | Aug 17, 2018 | M | 8,500 | D | — | Jun 15, 2027 | Common Stock | 8,500 | 91,500 | D |
Explanation of responses
- F1The stock option vested and became exercisable as to 1/4th of the shares subject to the option on May 22, 2018, and thereafter vests and becomes exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.